Barclays lowered the firm’s price target on Johnson & Johnson to $165 from $166 and keeps an Equal Weight rating on the shares following the Q1 report. The company reported strong Pharma results offset by slower growth in MedTech, driven primarily by a series of one-timers and prior year issues, the analyst tells investors in a research note. The firm says J&J maintained its 2025 outlook despite additional deal dilution and tariff impact.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Addex Therapeutics regains rights to ADX71149
- Legend Biotech Stock (LEGN) Up on Strong Sales and Bullish Analyst Outlook
- Johnson & Johnson price target raised to $164 from $162 at Raymond James
- Johnson & Johnson price target raised to $169 from $164 at Morgan Stanley
- Johnson & Johnson price target raised to $161 from $159 at BofA